Avasimibe (0, 0.25, 5, 10, 20, 40 and 80 µM; for 1, 2, and 3 days) reduces proliferation in the prostate cancer (PCa) cells.
Avasimibe (10 and 20 µM; 48 h) reduces the expression of β-catenin, Vimentin, N-cadherin, Snail and MMP9, which are tightly associated with epithelial-mesenchymal transition (EMT).
Avasimibe (10 and 20 µM) trigger cell cycle arrest via the E2F-1 signalling pathway in prostate cancer. Avasimibe induces G1 phase cell cycle arrest of PCa cells.
Avasimibe (10 and 20 µM) inhibits the metastasis of PCa cells.
Cell Viability Assay
Cell Line: |
PCa cells (PC-3 and DU 145) |
Concentration: |
0, 0.25, 5, 10, 20, 40 and 80 µM |
Incubation Time: |
1, 2, and 3 days |
Result: |
Dose dependently inhibited PC-3 and DU 145 cell viability. |
Western Blot Analysis
Cell Line: |
PCa cells (PC-3 and DU 145) |
Concentration: |
10 and 20 µM |
Incubation Time: |
48 hours |
Result: |
Reduced protein levels of EMT-related proteins (β-catenin, Vimentin, N-cadherin, Snail, MMP9 and E-cadherin). |
Cell Cycle Analysis
Cell Line: |
PCa cells (PC-3 and DU 145) |
Concentration: |
10 and 20 µM |
Incubation Time: |
48 hours |
Result: |
Induced G1 phase cycle arrest and altered the G1 phase-related protein levels in PCa cells. |